|
Apr 15
|
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
|
|
Feb 24
|
Entera Bio to Participate in Upcoming Events
|
|
Feb 19
|
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
|
|
Oct 4
|
Are Medical Stocks Lagging Argenx (ARGX) This Year?
|
|
Aug 1
|
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
|
|
Jul 23
|
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
|
|
Jun 20
|
7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months
|
|
Jun 20
|
Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich
|
|
Jun 17
|
3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
|
|
May 15
|
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
|
|
May 13
|
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
|
|
May 10
|
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
|
|
Apr 30
|
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
|
|
Apr 26
|
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Apr 18
|
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
|
|
Apr 15
|
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
|
|
Apr 12
|
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
|
|
Apr 9
|
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
|
|
Apr 8
|
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
|
|
Mar 26
|
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
|